Cellebrite DI Ltd. $CLBT Stock Position Raised by Thematics Asset Management

Thematics Asset Management boosted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 22.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,066,850 shares of the company’s stock after purchasing an additional 196,924 shares during the period. Thematics Asset Management owned 0.45% of Cellebrite DI worth $19,769,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in CLBT. Y.D. More Investments Ltd grew its stake in Cellebrite DI by 76.2% in the 2nd quarter. Y.D. More Investments Ltd now owns 441,579 shares of the company’s stock valued at $7,065,000 after buying an additional 191,020 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Cellebrite DI by 40.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock worth $6,652,000 after acquiring an additional 103,568 shares during the last quarter. Norwood Investment Partners LP bought a new stake in Cellebrite DI during the third quarter valued at about $4,274,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Cellebrite DI in the third quarter valued at about $19,457,000. Finally, Moody National Bank Trust Division acquired a new stake in shares of Cellebrite DI in the third quarter valued at about $2,670,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Price Performance

CLBT opened at $14.44 on Friday. The company has a market capitalization of $3.60 billion, a P/E ratio of 46.58, a P/E/G ratio of 2.23 and a beta of 1.30. The firm’s fifty day moving average price is $15.27 and its two-hundred day moving average price is $16.90. Cellebrite DI Ltd. has a fifty-two week low of $11.76 and a fifty-two week high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.14. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The company had revenue of $128.82 million during the quarter, compared to analysts’ expectations of $126.07 million. During the same quarter in the prior year, the company posted $0.10 EPS. The business’s revenue was up 28.8% on a year-over-year basis. On average, equities research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on CLBT. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Wall Street Zen lowered Cellebrite DI from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Needham & Company LLC cut their price target on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Cellebrite DI has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.